maritide vs retatrutide MariTide: Two Opposite Bets on GIP Retatrutide the wonder drug: What's

Presently, the Australian Diabetes Society (ADS) and ANZCA Perioperative Diabetes and Hyperglycaemia Guidelines (November 2022) provide the universal recommendation to withhold all non-insulin antihyperglycaemics on day of surgery, including GLP-1 agonists, with SGLT2 inhibitors to be withheld 2 days prior to surgery

CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head

The same medication that can cause allodynia in some patients at higher doses appears to treat neuropathic pain in others through anti-inflammatory mechanisms

Glutathione Glutathione is often called the master antioxidant for good reason: it plays a critical role in detoxifying the liver, flushing out heavy metals and environmental toxins, repairing damaged cells, and reducing oxidative stress throughout the body